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Abstract
We cloned the streptolysin O gene from the Streptococ-
cus pyogenes genome and tested the possibility of using
it as an anticancer reagent. Transient transfection of the
streptolysin O gene efficiently killed 293T cells after 12
hours of transfection as determined by lactate dehydro-
genase release and propidium iodide uptake. No caspase
activity was observed and necrosis was prominent during
streptolysin O-induced cell death. Biochemical analysis of
streptolysin O protein revealed that the deletion of only 5
amino acids from the COOH-terminal region of streptolysin
O, which is essential for cholesterol binding activity,
abolished its cell-killing activity, whereas the NH2-terminal
region was more resilient, i.e., up to 115 amino acids
could be deleted without changing its cell-killing activity.
We generated a streptolysin O-expressing adenovirus
and injected it into human cervical cancer cell–derived
tumors grown in a nude mouse model. Twenty-one days
postinjection, the average size of tumors in the streptoly-
sin O adenovirus–injected group was 29.3% of that
of the control PBS-treated group. Our results show that
the genes of pore-forming toxins, like streptolysin O
protein, have the potential to establish a novel class of
suicide gene therapeutic reagents. [Mol Cancer Ther
2006;5(6):1610–9]
Introduction
Suicide gene therapy has received much attention from
researchers and clinicians in cancer biology as an alterna-
tive therapy to conventional chemotherapy and radiother-
apy (1). Typically, suicide cancer gene therapy involves the
specific delivery of various cytotoxic genes, such as
apoptotic factors or enzyme-prodrug combinations, to
cancer cells. The subsequent expression of these genes
then induces cell death. Suicide cancer gene therapies
based on apoptotic factors such as p53 (2), FasL (3), Bax (4),
and tumor necrosis factor–related apoptosis inducing
ligand (5) have been extensively studied in athymic mice
models; however, they have intrinsic limitations as anti-
cancer gene therapeutic reagents because cancer cells
evolve resistance to apoptotic insults. For example, anti-
apoptotic molecules like Bcl-2, Bcl-xL, c-FILP, c-IAP, and
survivins are often overexpressed in many types of cancer
cells, and these confer resistance to cell death induced by
apoptotic factors (6). Enzyme-prodrug systems are repre-
sented by the herpes simplex virus thymidine kinase/
ganciclovir combination, the cytosine deaminase/5-fluoro-
cytosine combination, and the cytochrome P450/cyclo-
phosphamide combination system. These kill the targeted
cancer cells by interfering with the DNA replication or
transcription processes. Moreover, the toxic substances
produced by these combinations can spread out to the
neighboring cancer cells and induce consecutive cell death
(the bystander effect). The cancer cell–killing ability of
these systems is so powerful that the herpes simplex virus
thymidine kinase/ganciclovir system has already reached
phase I, II, or III clinical trials stage in several countries (7).
The two possible drawbacks of these enzyme-prodrug
systems are that a prominent bystander effect could cause
unwanted toxic effects in neighboring normal cells, and
that these systems tend to be less effective against cancer
cells that are not actively dividing. For example, human
melanoma is a slowly proliferating tumor, the doubling
time of melanoma cells has been reported to be 8.6 days, as
measured by the bromodeoxyuridine injection method (8).
Moreover, <3% of prostate cancer cells are known to be
actively dividing (9), and acute myeloid leukemia blasts do
not proliferate and only a minor proportion (1%) of human
leukemic cells are clonogenic progenitors (acute myeloid
leukemia colony–forming units; refs. 10, 11). Therefore, we
sought to develop a novel suicide gene therapeutic reagent
that is powerful, can overcome the antiapoptotic resistance,
and has an activity which is independent of the cell
proliferation rate.
Streptolysin O is a toxin secreted by bacteria from the
genus Streptococcus and is a prototype member of pore-
forming bacterial cytolysins along with Staphlyococcal a-toxin
and Escherichia coli hemolysin (12). Streptolysin O possesses
a single polypeptide chain with a molecular weight of
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f62 kDa. Streptolysin O binds specifically to membrane
cholesterol, and oligomerizes to create a ring structure that
consists of 45 to 50 units, which inserts into the membrane to
make a large pore diameter of 25 to 30 nm (13, 14).
Cell biologists have exploited the pore-forming property of
streptolysin O for macromolecule delivery, as evidenced by
a large number of published applications (15–17). When the
cell membrane is treated with streptolysin O, large mem-
brane pores are generated and the membrane becomes
permeable to extracellular DNA, RNA, peptides, and
proteins. Nucleated animal cells have the ability to recover
from such membrane damaged by using repair mechanisms
related to those involved in the repair of complement lesions
(18). Thus, using the above concept and elaborate experi-
mental protocols, macromolecules can be transferred to the
cell interior without inducing cell death. However, the
continual presence of streptolysin O-induced pores in a cell
membrane will result in cytolysis because of a loss of balance
between influxes and effluxes across the cell membrane.
We reasoned that membrane permeabilization by strep-
tolysin O-induced pore formation could be exploited to kill
malignant tumor cells, and furthermore, because the
cytolysis induced by streptolysin O pore formation causes
physical damage to the cell membrane, the streptolysin O-
induced cell death could overcome the antiapoptotic
resistance of cancer cells and the problems associated with
a low proliferation rate. Therefore, we initiated our studies
with a conventional plasmid expression analysis of
streptolysin O in a liposome-mediated transient transfec-
tion system. We found that transfected cells expressing
streptolysin O had cell membranes that became permeable
to extracellular macromolecules, and that eventually, these
transfected cells died. We extended our research by
developing an adenoviral expression system for streptoly-
sin O, and by using this high-efficiency gene transfer
methodology, we were able to establish the feasibility of
streptolysin O-mediated gene therapy against several
cancer cell lines. Furthermore, streptolysin O-expressing
adenovirus strongly inhibited tumor growth in a human
cervical cancer cell C33A tumor xenograft model.
Materials andMethods
Cell Lines
All cell lines, with the exception of Hep3B, which was
maintained in modified Eagle’s medium, were grown in
DMEM supplemented with 10% fetal bovine serum (Invi-
trogen, Groningen, the Netherlands). HEK293 (human
embryonic kidney fibroblasts), 293T (HEK 293 cell deriva-
tives that harbor SV40 large T antigen), C33A (human cer-
vical carcinoma cells), A549 (human lung carcinoma cells),
U343 (human glioma cells), and Hep3B (human hepatocel-
lular carcinoma cells) were purchased from the American
Type Culture Collection (Manassas, VA). All cell lines were
maintained at 37jC in a humidified atmosphere at 5% CO2.
Plasmid Constructs
Genomic DNA from Streptococcus pyogenes 700294D was
purchased from American Type Culture Collection. To
clone the streptolysin O gene from this genome, PCR was
done using ExTaq. Polymerase (Takara Bio, Shiga, Japan)
and amplified DNA fragments were subcloned into the
pcDNA3 vector. Sequence analysis revealed that the
amplified streptolysin O DNA differed from the previously
reported sequence (GenBank accession number,
AB0505250) at six amino acid positions (Ser50 ! Asn50,
Ile62 ! Thr62, Met69 ! Thr69, Ser90 ! Phe90, Val260 !
Ala260, and Asp327 ! Glu327). The DNA fragments of
streptolysin O corresponding to amino acids 33 to 574, 106
to 574, 116 to 574, 151 to 574, 1 to 569, and 1 to 530 were
amplified by PCR using ExTaq. Polymerase (Takara Bio)
using pcDNA3-streptolysin O as a template and subcloned
into pcDNA3 vector to generate pcDNA3-DN32 (tSLO),
pcDNA3-DN105, pcDNA3-DN115, pcDNA3-DN150,
pcDNA3-DC4, and pcDNA3-DC44, respectively. All inserts
and vectors were cleaved with EcoRI and XhoI restriction
enzymes (Promega, Madison, WI). In order to detect
expressed streptolysin O derivatives using antihemagglu-
tinin antibodies (Lab Vision, Fremont, CA), all inserts in
pcDNA3 vector were further subcloned between the EcoRI
and SalI sites of pSRaHA vector. cDNA fragments
encoding CrmA were amplified by PCR and subcloned
into pFlag-CMV2 vector (Sigma, St. Louis, MO) to generate
FL-CrmA. Bax and Bcl-xL constructs were generated as
described previously (19). The green fluorescent protein
(GFP)-caspase-8 construct was kindly provided by Dr.
Miyashita (National Research Institute for Child Health
and Development, Japan). All plasmid inserts were verified
by dideoxynucleotide sequencing. Detailed information on
the primer sequences used for PCR is available on request.
Immunoblot
Cells were harvested and centrifuged at 500  g for 10
minutes at 4jC. The cell pellets obtained were washed
once with 1 mL of PBS and lysed with 100 AL of 2
sample buffer [20 mmol/L Tris (pH 8.0), 2 mmol/L
EDTA, 2% SDS, 20 mmol/L DTT, 1 mmol/L Na3VO4, and
20% glycerol]. Lysates were sonicated in pulse mode,
boiled for 5 minutes, centrifuged at 10,000  g for 10
minutes at 4jC, and the supernatants obtained were
used as whole cell lysates. Protein quantification assays
were done using MicroBCA reagent (Pierce, Rockford, IL)
according to the manufacturer’s protocol. Typically, 50 Ag
of total cellular proteins were separated by SDS-PAGE
and the separated proteins were then transferred to a
nitrocellulose membrane which was then subjected to
standard Western blot using mouse antihemagglutinin
antibodies (Lab Vision), mouse anti-Bcl-xL (Santa Cruz
Biotechnology, Santa Cruz, CA), mouse anti-Bax (Santa
Cruz Biotechnology), and horseradish peroxidase–conju-
gated secondary antibodies (Santa Cruz Biotechnology).
All blotting membranes were stained with AmidoBlack
(Sigma) to ensure that equal amounts of proteins had been
loaded into each well.
Cell Death Assay Using Cotransfected GFP
The day before transfection, 5  105 293T cells were
plated in six-well culture plates (Nalgen Nunc Interna-
tional, Naperville, IL). The next day, the indicated amounts
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of DNA constructs were cotransfected with the pEGFPC
vector (Clontech, Palo Alto, CA) to 293T cells using
LipofectAMINE plus reagent according to the manufac-
turer’s protocol (Invitrogen). After 18 to 24 hours, cells
were harvested, washed once with PBS, and the intensity of
green fluorescence was monitored by fluorescence-activat-
ed cell sorting (FACS) to assay cell death (20). The FACS
profile of control transfection experiments, pEGFPC plus
pSRaHA, showed a peak at a position >4  102 on the x-
axis and we defined GFP-expressing cells located within
this region as GFPhigh cells. In control experiments with
mock vector, f35% of total cells were GFPhigh and the
percentages of GFPhigh cells was decreased as the trans-
fected cells died due to cytotoxic gene expression. The
percentage of dying/dead cells was also determined by
monitoring the DNA content of treated cells by FACS.
Monitoring Cell Permeability
The amount of lactate dehydrogenase (LDH) released by
transfected cells was measured using CytoTox 96 nonradio-
active cytotoxicity assay kits (Promega). To measure the
amount of propidium iodide uptake, treated cells were
harvested and centrifuged at 500  g for 10 minutes at 4jC.
The cell pellets obtained were washed once with 1 mL of PBS
and resuspended in 300 AL of PBS. Cells were stained with
propidium iodide at 0.2 Ag/mL and the percentage of
propidium iodide–permeable cells was measured by FACS.
ElectronMicroscopy
Adherent 293T cells were washed in PBS, fixed in 2.5%
glutaraldehyde at 4jC for 30 minutes and postfixed in 1%
OsO4 at room temperature for 20 minutes. The cells were
then dehydrated using increasing concentrations of alcohol
(30%, 50%, 70% plus 1% uranylacetate, 80%, 95%, and
100%), embedded in mixtures of Epon/alcohol (1:3 for 15
minutes, 1:2 for 30 minutes, 3:1 for 30 minutes, and pure
Epon for 2  30 minutes), and polymerized at 60jC for 2
days. The solidified blocks were cut into slices of 50 to 60
nm, which were then contrasted with 5% uranylacetate and
Reynold’s solution [80 mmol/L Pb(NO3)2, 120 mmol/L
sodium citrate, 160 mmol/L NaOH] and then viewed
under the electron microscope.
Biochemical Analysis of Streptolysin O-Induced Cell
Death
For caspase activity assays, monolayer cells were
harvested and then centrifuged at 450  g for 10 minutes
at 4jC. After removing the supernatant, cell pellets were
resuspended in 100 AL of cell lysis buffer [50 mmol/L
HEPES (pH 7.5), 1 mmol/L DTT, 0.1 mmol/L EDTA, and
0.1% CHAPS] and lysed by repeated freezing at 70jC and
thawing on ice. Lysates were then cleared by centrifugation
at 15,000  g for 20 minutes at 4jC, and the resulting
supernatants were used as cell extracts. Typically, 100 Ag
of cell extract was added to the caspase assay buffer
[100 mmol/L HEPES (pH 7.5), 10% sucrose, 0.1% CHAPS,
10 mmol/L DTT, and 200 Amol/L DEVD-pNA] with or
without 100 Amol/L of Boc-D. Mixtures were then
incubated at 37jC for 4 hours and the yellowish color
caused by the release of pNA was quantified using an
ELISA reader at 405 nm.
To analyze DNA content, cells were harvested and washed
once, as described above. The cell pellet was fixed overnight
with 70% ethanol, washed once with PBS, resuspended in
staining buffer (10 Ag/mL propidium iodide and 0.2 mg/mL
RNase A in PBS), and this cell suspension was kept at 4jC in
the dark until FACS analysis.
Construction of Modified Shuttle Vectors and the
Generation of Recombinant Adenoviruses
The stuffer DNA fragment flanked by two loxP sequences
was amplified from the pDNR-CMV plasmid (Clontech)
using ExTaq. Polymerase (Takara Bio) using the primers: 5¶-
gatccctctagagctagcgtcagtgagcgagg-3¶ and 5¶-gatccctcta-
gagtcgcggccgcttaacttcg-3¶ (XbaI sites are underlined). The
product was cloned into the XbaI site of pCA14 shuttle
vector to generate the pCA14-loxP construct. The GFP gene
from pEGFPC1 plasmid (Clontech) was amplified using
ExTaq. Polymerase (Takara Bio) using the primers: 5¶-
gatcccgaattcatggtgagcaagggcgagg-3¶ and 5¶-gatagacccgtcgact-
caacttgtacagctcgtccatgc-3¶ (EcoRI and SalI sites are under-
lined). The resulting DNA fragment was cloned between the
EcoRI and SalI sites of pCA14-loxP shuttle vector to generate
pCA14-loxP-GFP. cDNA encoding the deletion mutant of
streptolysin O (tSLO) was excised from pcDNA3-tSLO
plasmid using EcoRI and XhoI restriction enzymes and
cloned between the EcoRI and SalI sites of pCA14-loxP
shuttle vector to generate pCA14-loxP-tSLO. All inserts in
plasmids were verified by dideoxynucleotide sequencing.
The pCA14-loxP-GFP and pCA14-loxP-tSLO constructs were
then linearized byXmnI and PvuI digestion, respectively, and
the adenoviral vector vmdl324Bst (obtained from S.B. Verca,
University of Fribourg, Switzerland) containing the Ad5
genome deleted of E1 and E3 regions was linearized by BstBI
digestion. Linearized pCA14-loxP-GFP or pCA14-loxP-tSLO
were cotransformed into E. coli BJ5183 together with the
BstBI-digested vmdl324Bst for homologous recombination.
To verify the respective homologous recombinants, plasmid
DNA, purified from overnight E. coli culture, was digested
with HindIII and the digestion pattern was analyzed. Proper
homologous recombinant adenoviral plasmid DNA was
digested with PacI and transfected into 293 cells to generate
Ad-loxP-GFP and Ad-loxP-tSLO viruses. Cre-expressing
adenovirus, AdCreM2, was purchased from Microbix Bio-
systems Inc., Toronto, Ontario, Canada. Viruses were
propagated in 293 cells and purified using standard methods
(21). After viral generation, PCR amplification and DNA
sequencing, using primers specific for GFP or streptolysin O,
confirmed the correctness of the viruses. The titer (multiplic-
ity of infection, MOI) used in this study was determined
by the absorbance of the dissociated virus at 260 nm, where
1 absorbance unit is equivalent to 1012 viral particles per
milliliter. The particle-to-infectious unit ratio was 100:1.
Functional Analysis of GFP and Streptolysin O-
Expressing Adenoviruses In vitro
Cells grown in 24-well plates to 30% to 70% confluence
were infected with Ad-loxP-GFP or Ad-loxP-tSLO with or
without AdCreM2 virus at the indicated MOIs. After 3 days,
GFP expression was monitored under blue light excitation
using an Axiovert 100 inverted epifluorescence microscope
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(Carl Zeiss, Thornwood, NY) and the percentage of GFP-
expressing cells was determined by FACS. The viability of
infected cells was measured using a Cell Counting Kit-
8 (Dojindo Molecular Technologies, Kumamoto, Japan).
Briefly, 100 AL of WST-8[2-2(-methoxy-4-nitrophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monoso-
dium salt] solution was added to each 24-well cell culture.
After 3 hours of incubation at 37jC, the colored supernatant
was transferred to a 96-well microplate and absorbance at
450 nm was measured using a microplate reader. All assays
were done in triplicate. The DNA content of infected cells
was analyzed by FACS, as described above.
Treatment of Tumor-Bearing Nude Mice with Adeno-
viralVectors
C33A cells (1  107) were injected into the flanks of 6- to 8-
week-old male nude mice (Charles River Japan, Inc.,
Yokohama, Japan) to establish human tumor xenografts.
When tumor volumes reached 5 to 10 mm in diameter, mice
were randomized into three groups and the Ad-loxP-GFP or
Ad-loxP-tSLO viruses at 5  108 plaque-forming units in
50 AL of PBS were coinjected directly into the tumors with
AdM2Cre viruses at 2.5  108 plaque-forming units in 25 AL
of PBS, twice on alternating days. There was no appearance
of any leakage of viral solution into surrounding tissue.
Control tumors were injected with PBS only. Tumor growth
was measured twice or thrice times weekly until the end of
the study by measuring the length and width of each tumor
using a caliper. Tumor volumes were estimated using the
following formula: volume = 0.523 L w2.
Results
Transient Expression of Streptolysin O-Induced Cell
Death in 293TCells
Streptolysin O is a typical exotoxin that is produced by
group A streptococci. It is secreted by bacteria, binds to
cholesterol-containing membranes, and produces pores.
Because streptolysin O toxin acts outside of the plasma
membrane, it is uncertain whether streptolysin O expressed
in mammalian cells possess cytolytic activity and kills host
cells. To test this possibility, we initially cloned the
streptolysin O gene obtained from the genomic DNA of
S. pyogenes into the mammalian expression vector,
pcDNA3. Sequence analysis revealed that it differed at six
amino acids from the reported streptolysin O sequence
(GenBank accession number, AB050250; Materials and
Methods). The cloned streptolysin O gene was further
subcloned into pSRaHA expression vector in order to
detect the expressed streptolysin O by Western blotting
with antihemagglutinin antibody (Materials and Methods).
However, we could not detect a western band from the
hemagglutinin-tagged full-length streptolysin O protein
(data not shown), and thus, we used a truncated version of
streptolysin O, which lacked the 32 NH2-terminal amino
acids of full-length streptolysin O (tSLO, 542 amino acids).
When the tSLO gene was transiently transfected into
293T cells, the cells became small in size and detached from
culture plates (Fig. 1A). Transfection with proapoptotic Bax
produced a similar morphology, but antiapoptotic Bcl-xL
and control mock vector did not change the cell morphol-
ogy (Fig. 1A). We cotransfected a GFP reporter with each
expression plasmid and measured the fluorescence inten-
sity by FACS to estimate the viability of the transfected
cells. As shown in Fig. 1B, the expression of death-inducing
Bax or tSLO gradually lowered the fluorescence intensity in
transfected cells as the amount of expression plasmid was
increased, whereas mock vector and Bcl-xL expressions
maintained similar levels of fluorescence intensity inde-
pendent of the amount of expression plasmid added.
Therefore, streptolysin O expressed in 293T cells was
found to be cytotoxic despite differences between the
bacterial and mammalian expression systems. The expres-
sion level of all expression plasmids were monitored by
Western blotting (Fig. 1C).
Figure 1. Overexpression of the
streptolysin O gene induces cell
death in 293T cells. The streptolysin
O gene from S. pyogenes was
subcloned into pSRa expression vec-
tor and transiently transfected into
the 293T cell line. A, after 16 h of
transfection, cell morphology was
monitored under the microscope.
Cells were transfected with 500 ng
of the expression construct. B, GFP
reporter plasmid was cotransfected
with the indicated amounts of each
expression construct, and cell viabil-
ity was assessed by measuring the
intensity of green fluorescence by
FACS after 24 h of transfection.
Columns, mean of triplicate experi-
ments; bars, +1 SD. C, the expres-
sion of each transfected gene in B
was monitored by Western blot
analysis using antibody against hem-
agglutinin peptide, Bcl-xL, or Bax
antibody.
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The Integrity of the Plasma Membrane Is Disrupted
by tSLOExpression
Streptolysin O toxin secreted by bacteria creates large
pores in the target cell plasma membrane, and thus, large
molecules that normally cannot pass through the membrane
are able to freely pass. We wanted to determine whether the
observed cytotoxicity in tSLO-transfected cells was the result
of membrane pores generated by the expressed tSLO. Thus,
we monitored the level of LDH release from the cytosol of
transfected cells (Fig. 2A). LDH has a molecular weight of
f125 kDa, and cannot freely traverse the plasma membrane,
thus, the LDH release assay has been widely used to
measure the level of cell lysis caused by membrane attack by
perforin, complement system, or pore-forming toxins.
As shown in Fig. 2A, the expression of control mock
vector caused a release of <10% of LDH, and Bax induced
the release of 23% after 24 hours of transfection. In
contrast, the level of LDH release due to tSLO expression
was higher (f60%) indicating that the plasma membrane
is readily permeabilized by tSLO. Moreover, the release of
LDH was more rapid than that of Bax. Bax induces cell
death via apoptotic pathways, which usually retain an
intact plasma membrane until the late phase. In contrast,
the membrane integrity of tSLO-transfected cells was
rapidly disrupted, which implies that a cell death
pathway other than apoptosis is activated during tSLO-
induced cell death. This rapid disruption of plasma
membrane integrity was also monitored using a propi-
dium iodide uptake experiment (Fig. 2B). tSLO-expressing
cells were readily stained by exogenous propidium iodide
dye, which cannot penetrate intact cell membranes. Bax-
expressing cells were also stained with propidium iodide
but the level of staining was significantly lower than that
of tSLO-expressing cells.
To differentiate Bax-induced cell death and tSLO-induced
cell death more clearly, the ultrastructures of transfected
cells were monitored under the electron microscope
(Fig. 2C). After 16 hours of transfection, Bax-expressing
cells had a shrunken appearance, shed fragmented cell
debris in a budding manner, and maintained a dense
cytoplasm. However, tSLO-expressing cells showed many
vacuoles and a less dense cytoplasm. Thus, we concluded
that tSLO induces nonapoptotic cell death by creating pores
in the plasma membrane.
Biochemical Analysis of tSLO-Induced Cell Death
Caspases are proteolytic enzymes that are activated
during various forms of cell death. To test the possibility
that caspases are involved in tSLO-induced cell death, we
measured cellular caspase activities using the caspase-
3-specific peptide substrate DEVD-pNA. The classical
proapoptotic proteins, Bax or caspase-8, activated cellular
caspase-3, whereas treatment with the pan-caspase inhib-
itor, Boc-D, prevented this activation. In contrast, tSLO did
not activate cellular caspase-3, indicating that tSLO-
induced cell death does not involve caspase-3 activation
(Fig. 3A).
As tSLO-induced cell death seems to be independent of
caspases, we tested the hypothesis that tSLO-induced cell
Figure 2. Streptolysin O expression increases plasma membrane permeability and disrupts the plasma membrane. A, the release of cytosolic LDH into
culture medium by membrane-permeabilized cells was monitored using a CytoTox 96 nonradioactive cytotoxicity assay kit. 293T cells were transfected
with 500 ng of each expression construct and the culture media was harvested at the indicated times. Points, mean of triplicate experiments; bars, F1 SD.
B, the uptake of propidium iodide dye by transfected 293T cells was monitored by FACS. Five hundred nanograms of each expression construct was used
for transfection and the culture was harvested after 16 h. C, the morphologies of dying cells were monitored using an electron microscope. Cells grown in
six-well culture plates were transiently transfected with 500 ng of each expression construct. After 16 h of transfection, cells were treated as described in
Materials and Methods, and cell morphology was observed under the electron microscope.
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death should not be blocked by the overexpression of potent
antiapoptotic molecules, which is a mechanism commonly
used by neoplastic cells to prevent apoptosis (ref. 6; Fig. 3B).
Bax-induced cell death was inhibited by the overexpression
of Bcl-xL and caspase-8-induced cell death was inhibited by
the overexpression of CrmA. However, tSLO-induced cell
death was not affected by the overexpression of either of
these antiapoptotic molecules. Even the pan-caspase inhib-
itor Boc-D did not affect tSLO-induced cell death. These
data show that streptolysin O protein expressedwithin 293T
cells kills them via a necrotic pathway.
Streptolysin ODeletion Study
Several deletion mutants of streptolysin O were generated
in order to identify the region responsible for the observed
cell death (Fig. 4A). All deletion constructs were fused to
hemagglutinin-tag to enable the expressed protein to be
detected with antihemagglutinin antibody. Full-length strep-
tolysin O protein fused with hemagglutinin-tag permeabi-
lized cell membranes and killed transfected cells (Fig. 4C).
However, we could not detect the hemagglutinin-streptoly-
sin O protein by Western blotting with antihemagglutinin
antibody, suggesting that the end of the NH2-terminal region
of streptolysin O is rapidly cut out during the posttransla-
tional processing (Fig. 4B). Deletions up to 115 amino acids
from the NH2 terminus induced cell death when expressed
in 293T cells (Fig. 4C). However, when 150 amino acids from
the NH2 terminus were removed, the cell-killing activity of
streptolysin O disappeared almost completely, indicating
that these terminal 150 amino acids are essential for strep-
tolysin O-induced membrane permeabilization (Fig. 4C).
However, in contrast to the NH2 terminus, deletions of only
five amino acids from the COOH terminus abolished the
cell-killing activity of streptolysin O (Fig. 4C). The strict
requirement for an ‘‘intact COOH-terminal region’’ is
explained by the identification of this region as a cholester-
ol-binding region (12). Thus, our deletion study emphasizes
the importance of cholesterol binding on the action of
streptolysin O and provides indirect evidence that strepto-
lysin O protein expressed in mammalian cells behaves like
its bacterial counterpart.
Generation of Ad-loxP-tSLOAdenovirus
In order to examine the possibility that the streptolysin O
gene can be used as an anticancer gene therapeutic reagent,
we generated a replication-deficient adenovirus that can
express the tSLO gene. Because tSLO is a cytotoxic protein,
we used a Cre-inducible system that is widely used for toxic
gene expression to circumvent the difficulties of virus
packing in the 293A cell line (Fig. 5A). Recombinant
adenoviral genomes encoding loxP-GFP or loxP-tSLO were
constructed and transfected into a 293A cell line, as
described in ‘‘Materials and Methods.’’ Ten days posttrans-
fection into the 293A cells, the cytopathic effect became
evident. Cell culture supernatants were then harvested and
centrifuged to obtain a clear culture supernatant. Aliquots
were analyzed by PCR to confirm the presence of
recombinant adenovirus encoding loxP-GFP or loxP-tSLO
(data not shown). We named these adenoviruses, Ad-loxP-
GFP and Ad-loxP-tSLO, and further amplified and purified
them, using standard CsCl gradient methods (Materials and
Methods). To test the functionality of the purified adenovi-
rus, we infected the human cervical carcinoma C33A cell line
and monitored the green fluorescence emitted by GFP.
Infection with only Ad-loxP-GFP, and not Cre virus
(AdM2Cre), showed a slight increase in the number of
green-colored cells, indicating that the loxP system is leaky.
When C33A cells were coinfected with Ad-loxP-GFP and
AdM2Cre, GFP overexpression was induced and >80% of
the cell population was positive for the green color (Fig. 5B).
This control experiment confirmed the functionality of the
purified adenovirus and of the Cre-loxP system. We also
tested the functionality of Ad-loxP-tSLO in C33A cells. As
shown in Fig. 5C, coinfection with Ad-loxP-tSLO and
AdM2Cre caused marked C33A cell death. The control
Ad-loxP-GFP virus in combination with AdM2Cre showed
an intermediate level of cytotoxicity, and Ad-loxP-GFP or
Ad-loxP-tSLO without AdM2Cre showed little cytotoxicity
at a MOI <10. All these combinations showed remarkable
cytotoxicity with MOIs >20 in the C33A cell line.
Figure 3. Biochemical analysis characterized streptolysin O-induced cell
death as necrosis. A, 293T cells were transfected with the indicated
amounts of each DNA construct and incubated for 24 h. Cell lysates were
prepared and the activity of cellular caspase-3 was assayed as described in
Materials and Methods. Pan-caspase inhibitor Boc-D was added to the
culture where indicated at a final concentration of 100 Amol/L. B, the
inhibition of cell death by cellular antiapoptotic protein Bcl-xL, viral
antiapoptotic protein CrmA or peptide pan-caspase inhibitor Boc-D was
assayed by measuring the green fluorescence emitted by coexpressed GFP
reporter protein by FACS. Cells were transfected with 500 ng of Bax, GFP-
caspase-8, or hemagglutinin-tSLO expression construct. The expression
construct for Bcl-xL or CrmA (500 ng) was cotransfected with each cell
death inducing DNA construct or pan-caspase inhibitor Boc-D was added
to the culture where indicated at a final concentration of 100 Amol/L.
Columns, mean of triplicate experiments; bars, F1 SD.
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TheAntitumor Effect of Ad-loxP-Streptolysin OAde-
novirus In vitro
The time-dependent anticancer effect of Ad-loxP-tSLO
adenovirus was monitored in several cell lines. Six days
after coinfection with Ad-loxP-tSLO (20 MOI) and AdM2-
Cre (10 MOI), >90% cell death was observed in C33A and
A549 cells (Fig. 6), whereas the control PBS group did not
show any remarkable cytotoxic effect. However, coinfection
with Ad-loxP-GFP (20 MOI) and AdM2Cre (10 MOI)
produced an intermediate level of cytotoxicity in these
cells, suggesting that the expression of GFP and/or Cre
protein exerts a toxic effect in these cell lines. There have
been reports that expression of GFP or Cre proteins are
toxic to cell lines under specific experimental conditions
(22–25). When MCF-7 and PC-3 cells were used as target
cells,f60% cell death was observed for the same viral dose
Figure 4. Deletion study of streptolysin O protein showed a strict
requirement for an intact COOH terminus. A, a diagram of the deletion
constructs used in this study. All deletion constructs were fused to
hemagglutinin tag at the NH2 terminus. Locations of transmembrane
helixes 1 and 2 (TMH1 and TMH2 ), domain 4, and the cholesterol binding
domain of streptolysin O are indicated. B, the expression of each deletion
construct was monitored by Western blot analysis using antihemagglutinin
antibody. Cells grown in six-well culture plates were transfected with 500
ng of each DNA construct, incubated for 24 h and harvested for Western
blot analysis. After one set of Western blot with antihemagglutinin
antibody, the blotting membrane was stripped and reblotted with antibody
against ERK1/2 to monitor the amount of protein loaded onto the protein
gel. Small arrows, the deletion mutant detected using its molecular
weight. C, the degree of plasma membrane permeabilization was
monitored using an LDH release assay kit as described in Materials and
Methods. Cells were transfected and harvested as in B. Columns, mean of
triplicate experiments; bars, F1 SD.
Figure 5. Generation of Cre-inducible streptolysin O expressing adeno-
virus and functional testing. A, diagram of how the modified shuttle vector
works for the inducible expression of GFP or streptolysin O protein. B,
C33A cells grown in 24-well culture plates were infected with 10 MOIs of
Ad-loxP-GFP with or without 5 MOIs of AdM2Cre, incubated for 3 d, and
harvested. The Cre-inducible expression of GFP was monitored by
fluorescence microscopy and FACS. C, the cell death induced by the
Cre-inducible expression of streptolysin O protein was measured by
viability assay as described in Materials and Methods. C33A cells grown in
24-well culture plates were infected with the indicated MOIs of Ad-loxP-
GFP or Ad-loxP-streptolysin O with or without AdM2Cre, incubated for 3
d, and then viability reagent was added to the cultures. The ratio of
AdM2Cre to loxP-Ad-GFP or loxP-Ad-streptolysin O was 1:2 at all MOIs.
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and time as in C33A and A549 cells (Fig. 6). In contrast to
C33A and A549 cells, coinfection with the control Ad-loxP-
GFP (20 MOI) and AdM2Cre (10 MOI) viruses showed little
cytotoxicity in MCF-7 and PC-3 cells. We measured the
expression level of GFP by FACS and found a strong
correlation between the level of GFP expression and the
level of cytotoxicity (data not shown). Thus, differences in
the level of cell death in each cell line can be explained by
differences in the sensitivity of each cell line to viral
infection. We cannot exclude an alternative possibility that
low-level contamination with wild-type recombinant-com-
petent adenovirus induces the observed background cell
death.
Antitumor Effect of Ad-loxP-tSLOAdenovirus In vivo
We next evaluated the antitumor effect of tSLO-
expressing adenovirus by injecting adenoviruses into
tumors established from human cervical cancer xeno-
grafts, C33A, in nude mice. Tumors were generated by
the s.c. injection of cells into flanks, and when tumors
reached an average of 90 to 100 mm3, 5  108 plaque-
forming units of Ad-loxP-tSLO and 2.5  108 plaque-
forming units of AdM2Cre were coinjected directly into
tumors on days 0 and 2. As shown in Fig. 7, control
tumors, which were treated with PBS, increased to an
average size of 1,643 F 467 mm3 21 days after virus
injection, whereas tumor growth was significantly
inhibited in mice coinjected with the replication-incom-
petent Ad-loxP-tSLO/AdM2Cre. More specifically, the
average tumor size in the Ad-loxP-tSLO/AdM2Cre–
treated animals was 481 F 184 mm3 21 days after
coinjection, which is >70% reduction in average tumor
size (P < 0.001, versus PBS treated mice, n = 8). Control
tumors, which received Ad-loxP-GFP/AdM2Cre, showed
an intermediate level of growth inhibition, which is
consistent with the in vitro data. However, Ad-loxP-
tSLO/AdM2Cre– treated tumors were still 47% smaller
21 days after coinjection (P < 0.05, versus Ad-loxP-GFP/
AdM2Cre– treated mice, n = 8). Throughout the course of
this study, no systemic toxicity, such as diarrhea, loss of
weight, or cachexia was observed.
Discussion
Toxins have the ability to kill cells efficiently, and thus,
many toxins have been examined as potential anticancer
agents, as immunotoxins or in viral gene therapy. Diph-
theria toxin is one of the best-studied molecules as a suicide
gene therapeutic reagent. It efficiently ADP-ribosylates
elongation factor 2, and thus, blocks the translational
machinery of target cells (26). It is estimated that a single
molecule of diphtheria toxin can kill target cells (27), and
many studies have successfully used its toxicity to
eradicate target cancer cells (28–32). Plant-derived ricin
and pseudomonas exotoxin use a mechanism similar to that
of diphtheria toxin to kill target cells, and have been
examined as effective anticancer reagents (33, 34). Howev-
er, all toxins that have been tested as suicide gene
therapeutic reagents are known to act ‘‘inside’’ of cells.
Conversely, pore-forming toxins act ‘‘outside’’ the cell
membrane naturally, and thus, they have been used as
immunotoxins or native proteins for anticancer agents
rather than as suicide gene therapeutic reagents (35–37).
We were not sure whether a representative pore-forming
toxin, streptolysin O, synthesized using eukaryotic ex-
pression machinery, could function ‘‘inside’’ the cell
membrane. Our initial trial with streptolysin O DNA-
lipid complexes in the 293T cell line showed that
intracellular streptolysin O had significant cytotoxicity
(Fig. 1). Biochemical analysis of this streptolysin O-
induced cytotoxicity revealed that the plasma membranes
of streptolysin O-expressing cells were permeabilized, and
that cytoplasmic contents leaked out of cells, which
Figure 6. Streptolysin O-expressing
adenovirus kills various cancer cell
lines effectively. Four different cancer
cell lines were grown in 24-well culture
plates and infected with 10 MOIs of
Ad-loxP-GFP or Ad-loxP-streptolysin O
along with 5 MOIs of AdM2Cre.
Infected cells were harvested after the
indicated times and the percentages of
dying/dead cells containing subge-
nomic DNA were measured by staining
cellular DNA with propidium iodide dye
as described in Materials and Methods.
PBS-treated cells viewed as negative
controls.
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eventually died due to plasma membrane disintegration.
No caspase activation was observed in the present study,
indicating that cells died from necrosis. These findings
coincide with the cell death induced by native streptolysin
O toxin and suggest that streptolysin O protein synthe-
sized within eukaryotic cells acts in a similar way to
native streptolysin O toxin. Our deletion analysis of the
streptolysin O protein further supports this viewpoint
(Fig. 4). The COOH-terminal region of streptolysin O is
the cholesterol-binding region, and the structure of this
region has been suggested to be very compact. Only a
single amino acid deletion in this region disabled the
cholesterol-binding property of streptolysin O (38). In
contrast, the NH2-terminal region of streptolysin O is
more tolerant and deletions of >100 amino acids retained
streptolysin O function (38). These structural properties
were repeated by streptolysin O protein synthesized
within eukaryotic cells (Fig. 4). Up to 115 amino acids of
the NH2-terminal region were found to be dispensable for
streptolysin O-induced cytotoxicity, whereas the deletion
of only 5 amino acids from COOH-terminal region
markedly depressed the cytotoxicity.
The biochemical properties of streptolysin O-induced cell
death have several interesting features that could be
potentially advantageous for treating cancer cells. First,
cellular caspases remained at a basal level during strepto-
lysin O-induced cell death, which implies that cellular ATP
has been depleted to a level that can’t support the activation
of cellular caspases. Most anticancer reagents damage DNA
and initiate DNA damage–induced apoptosis or necrosis,
and whereas these anticancer reagents are effective against
sensitive cancer cells, some cancer cells are less sensitive to
these drugs. The depletion of ATP from cells proved to be a
crucial method of killing cancer cells, as ATP is a key cellular
metabolite. Several studies have found that ATP-depleting
agents significantly enhanced the anticancer activity of
chemotherapeutic reagents, and that ATP-depleting peptides
or polymers are effective against drug-resistant cancer cells
(39–41). Second, expressed streptolysin O damages the
plasma membrane directly, and thus, the antiapoptotic
machinery developed during cancer cell evolution is unable
to inhibit streptolysin O-induced cancer cell death. Third, as
streptolysin O-induced cell death is not dependent on the
cellular proliferation rate, cancer gene therapy based on the
streptolysin O gene may be effective against tumors with
low proliferation rates, such as prostate cancer.
It is worth mentioning that the use of the streptolysin O
gene for tumor cell–killing offers some advantages over
the use of intact streptolysin O toxin protein. First,
streptolysin O protein needs to oligomerize to create
pores in the cell membrane, which is difficult if intact
streptolysin O protein or antibody conjugated to strepto-
lysin O protein is injected into a patient. Second, humans
have antistreptolysin antibodies that clear injected strep-
tolysin O protein and cause a deleterious inflammatory
response, which has proven to be one of the most difficult
problems associated with the use of pore-forming toxins
as anticancer reagents. Third, streptolysin O binding to
the cell membrane is not tumor-specific, and thus, if intact
streptolysin O protein is injected into a patient, it will also
attack normal cells. The streptolysin O-expressing adeno-
virus used in the present study is not specific against
tumors, and thus, we created this specificity by intra-
tumorally injecting the adenovirus. However, the virus
can be modified to target tumor cells either by attaching
tumor-specific promoters upstream of the streptolysin O
gene or by changing the adenoviral fiber proteins to bind
to tumor cell surface proteins (42, 43). It would be
promising to integrate the streptolysin O gene with
oncolytic viruses. This strategy may decrease the virus
titer required, which is important because the adenovirus
itself has significant side effects when used at a high titer,
as shown by our results and those of others (44).
In summary, we report the successful use of the
streptolysin O gene as an anticancer reagent in both cell
culture and in a C33A xenograft nude mouse model. In this
study, prototype adenovirus was used to deliver the strep-
tolysin O gene into a tumor, but obviously, the streptolysin
O gene can easily be implemented into other cancer-specific
gene delivery systems. We believe that other kinds of pore-
forming toxins, which are abundant in nature, should also
be tested as potential anticancer gene therapies.
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